Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Morgan

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Human Gene Therapy|August 30, 2018
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid TumorsMichael A Morgan, Axel Schambach
Frontiers in Immunology|November 14, 2018
Engineering CAR-T Cells for Improved Function Against Solid TumorsMichael A Morgan, Axel Schambach
Current Medicinal Chemistry|February 7, 2003
Gene silencing mediated by small interfering RNAs in mammalian cellsMichaela Scherr, Michael A Morgan, Matthias Eder
Signal Transduction and Targeted Therapy|July 26, 2021
Targeted cytokine delivery: cell therapy to remodel the pre-metastatic nicheMichael A Morgan, Lucas Lange, Axel Schambach
Signal Transduction and Targeted Therapy|July 6, 2022
Prime time for base editing in the mitochondriaMichael A Morgan, Lucas Lange, Axel Schambach
Annals of Hematology|January 5, 2006
Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemiasMichael A Morgan, Christoph W M Reuter
Cancer Research|November 4, 2017
Uncoupling the Oncogenic EngineAxel Schambach, Juliane W Schott, Michael A Morgan
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2007
Going from genes to proteins in myelodysplastic syndromesArnold Ganser, Michael A Morgan, Eva M Weissinger
Frontiers in Immunology|September 9, 2020
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK CellsMichael A Morgan, Hildegard Büning, Martin Sauer, et al.
Gene Therapy|March 23, 2021
Retroviral gene therapy in Germany with a view on previous experience and future perspectivesMichael A Morgan, Melanie Galla, Manuel Grez, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Human Gene Therapy|August 30, 2018
Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid TumorsMichael A Morgan, Axel Schambach
Frontiers in Immunology|November 14, 2018
Engineering CAR-T Cells for Improved Function Against Solid TumorsMichael A Morgan, Axel Schambach
Current Medicinal Chemistry|February 7, 2003
Gene silencing mediated by small interfering RNAs in mammalian cellsMichaela Scherr, Michael A Morgan, Matthias Eder
Signal Transduction and Targeted Therapy|July 26, 2021
Targeted cytokine delivery: cell therapy to remodel the pre-metastatic nicheMichael A Morgan, Lucas Lange, Axel Schambach
Signal Transduction and Targeted Therapy|July 6, 2022
Prime time for base editing in the mitochondriaMichael A Morgan, Lucas Lange, Axel Schambach
Annals of Hematology|January 5, 2006
Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemiasMichael A Morgan, Christoph W M Reuter
Cancer Research|November 4, 2017
Uncoupling the Oncogenic EngineAxel Schambach, Juliane W Schott, Michael A Morgan
Proceedings of the National Academy of Sciences of the United States of America|January 24, 2007
Going from genes to proteins in myelodysplastic syndromesArnold Ganser, Michael A Morgan, Eva M Weissinger
Frontiers in Immunology|September 9, 2020
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK CellsMichael A Morgan, Hildegard Büning, Martin Sauer, et al.
Gene Therapy|March 23, 2021
Retroviral gene therapy in Germany with a view on previous experience and future perspectivesMichael A Morgan, Melanie Galla, Manuel Grez, et al.
Pageof 4